נגישות
menu      
Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Inhibition of Neovascularization and Tumor Growth, and Facilitation of Wound Repair, by Halofuginone, an Inhibitor of Collagen Type I Synthesis
Year:
1999
Source of publication :
Neoplasia
Authors :
Pines, Mark
;
.
Volume :
1
Co-Authors:
Abramovitch, R., Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
Dafni, H., Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
Neeman, M., Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
Nagler, A., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Pines, M., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan 50250, Israel
Facilitators :
From page:
321
To page:
329
(
Total pages:
9
)
Abstract:
Halofuginone, an inhibitor of collagen α1(l) gene expression was used for the treatment of subcutaneously implanted C6 glioma tumors. Halofuginone had no effect on the growth of C6 glioma spheroids in vitro, and these spheroids showed no collagen α1(l) expression and no collagen synthesis. However, a significant attenuation of tumor growth was observed in vivo, for spheroids implanted in CD-1 nude mice which were treated by oral or intraperitoneal (4 μg every 48 hours) administration of halofuginone. In these mice, treatment was associated with a dose-dependent reduction in collagen α1(l) expression and dose- and time-dependent inhibition of angiogenesis, as measured by MRI. Moreover, halofuginone treatment was associated with improved re-epithelialization of the chronic wounds that are associated with this experimental model. Oral administration of halofuginone was effective also in intervention in tumor growth, and here, too, the treatment was associated with reduced angiogenic activity and vessel regression. These results demonstrate the important role of collagen type I in tumor angiogenesis and tumor growth and implicate its role in chronic wounds. Inhibition of the expression of collagen type I provides an attractive new target for cancer therapy.
Note:
Related Files :
Animal
Animals
biosynthesis
Magnetic Resonance Imaging
Male
metabolism
mice
Pathology
quinazolinone derivative
Show More
Related Content
More details
DOI :
Article number:
Affiliations:
Database:
Scopus
Publication Type:
article
;
.
Language:
English
Editors' remarks:
ID:
21067
Last updated date:
02/03/2022 17:27
Creation date:
16/04/2018 23:41
Scientific Publication
Inhibition of Neovascularization and Tumor Growth, and Facilitation of Wound Repair, by Halofuginone, an Inhibitor of Collagen Type I Synthesis
1
Abramovitch, R., Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
Dafni, H., Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
Neeman, M., Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
Nagler, A., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel
Pines, M., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan 50250, Israel
Inhibition of Neovascularization and Tumor Growth, and Facilitation of Wound Repair, by Halofuginone, an Inhibitor of Collagen Type I Synthesis
Halofuginone, an inhibitor of collagen α1(l) gene expression was used for the treatment of subcutaneously implanted C6 glioma tumors. Halofuginone had no effect on the growth of C6 glioma spheroids in vitro, and these spheroids showed no collagen α1(l) expression and no collagen synthesis. However, a significant attenuation of tumor growth was observed in vivo, for spheroids implanted in CD-1 nude mice which were treated by oral or intraperitoneal (4 μg every 48 hours) administration of halofuginone. In these mice, treatment was associated with a dose-dependent reduction in collagen α1(l) expression and dose- and time-dependent inhibition of angiogenesis, as measured by MRI. Moreover, halofuginone treatment was associated with improved re-epithelialization of the chronic wounds that are associated with this experimental model. Oral administration of halofuginone was effective also in intervention in tumor growth, and here, too, the treatment was associated with reduced angiogenic activity and vessel regression. These results demonstrate the important role of collagen type I in tumor angiogenesis and tumor growth and implicate its role in chronic wounds. Inhibition of the expression of collagen type I provides an attractive new target for cancer therapy.
Scientific Publication
You may also be interested in